Detalhe da pesquisa
1.
Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
Mult Scler
; 30(3): 369-380, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38286755
2.
Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
Mult Scler
; 30(1): 35-43, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37982154
3.
Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
Mult Scler
; 29(10): 1257-1265, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37537928
4.
The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
Mult Scler
; 29(3): 427-435, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36550636
5.
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis.
Mult Scler
; 29(7): 846-855, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37204214
6.
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
Mult Scler
; 28(5): 801-816, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465252
7.
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.
Mult Scler
; 28(2): 198-205, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34014144
8.
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Mult Scler
; 28(10): 1591-1605, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380078
9.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Mult Scler
; 28(10): 1526-1540, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261318
10.
Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.
Mult Scler
; 28(1): 16-28, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34850641
11.
Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.
BMC Neurol
; 22(1): 211, 2022 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35672686
12.
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
N Engl J Med
; 379(9): 846-855, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30157388
13.
New applications for independent activities of daily living in measuring disability in multiple sclerosis.
Mult Scler
; 27(1): 97-106, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31933419
14.
Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis.
Mult Scler
; 27(5): 742-754, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32672101
15.
Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
Mult Scler
; 27(11): 1781-1789, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33399503
16.
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Mult Scler
; 27(13): 2014-2022, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33635141
17.
Juxtacortical susceptibility changes in progressive multifocal leukoencephalopathy at the gray-white matter junction correlates with iron-enriched macrophages.
Mult Scler
; 27(14): 2159-2169, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33749379
18.
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Mult Scler
; 27(10): 1564-1576, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33205682
19.
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
Mult Scler
; 27(9): 1384-1390, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054533
20.
Importance of incorporating quantitative imaging biomarker technical performance characteristics when estimating treatment effects.
Clin Trials
; 18(2): 197-206, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33426918